ストックスクリーナーアプリを入手
13.57
7.10%
0.90
アフターアワーズ：
13.57
前日終値:
$12.67
開ける：
$12.54
24時間の取引高:
740.39K
Relative Volume:
1.09
時価総額：
$784.79M
収益：
$1.23M
当期純損益:
$-214.90M
株価収益率:
-3.2919
EPS:
-4.1222
ネットキャッシュフロー:
$-151.25M
1週間 パフォーマンス:
+4.22%
1か月 パフォーマンス:
-25.32%
6か月 パフォーマンス:
-58.16%
1年 パフォーマンス:
-58.13%
1日の値動き範囲:
$12.53
$13.81
1週間の範囲:
$12.04
$13.81
52週間の値動き範囲:
$10.91
$40.49
Spyre Therapeutics Inc Stock (SYRE) Company Profile
SYRE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
13.57 | 784.79M | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-08 | 開始されました | Leerink Partners | Outperform |
| 2025-03-18 | 開始されました | Wolfe Research | Outperform |
| 2024-09-04 | 開始されました | Wedbush | Outperform |
| 2024-07-16 | 開始されました | Evercore ISI | Outperform |
| 2024-05-02 | 開始されました | Robert W. Baird | Outperform |
| 2024-03-01 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 開始されました | BTIG Research | Buy |
| 2023-12-11 | 開始されました | Guggenheim | Buy |
| 2023-12-11 | 開始されました | Jefferies | Buy |
| 2020-05-04 | 開始されました | Piper Sandler | Overweight |
| 2019-03-21 | 開始されました | JP Morgan | Overweight |
| 2018-09-04 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 開始されました | Evercore ISI | Outperform |
| 2018-03-14 | 繰り返されました | Needham | Buy |
すべてを表示
Spyre Therapeutics Inc (SYRE) 最新ニュース
Vanguard Group Inc. Buys 330,553 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Q1 Earnings Estimate for SYRE Issued By Leerink Partnrs - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $50.33 Consensus Price Target from Brokerages - Defense World
Corebridge Financial Inc. Has $401,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Leerink Partnrs Upgrades Spyre Therapeutics (NASDAQ:SYRE) to “Strong-Buy” - Defense World
KLP Kapitalforvaltning AS Invests $182,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Now Covered by Analysts at Leerink Partners - Defense World
Leerink Partners Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform Recommendation - Nasdaq
Leerink Partners Initiates Spyre Therapeutics With Outperform Rating, $45 Price Target - marketscreener.com
Biotech Spyre Therapeutics Awards 93,200 Stock Options in Key Talent Push - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week LowHere's Why - MarketBeat
Teacher Retirement System of Texas Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up – What’s Next? - Defense World
Swiss National Bank Buys 19,000 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Starts Dosing in Phase 1 Trial for IL-23 Antibody SPY003 - Marketscreener.com
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody - PR Newswire
Game-Changing IL-23 Antibody Enters Clinical Trials: Quarterly Dosing Could Transform Treatment - Stock Titan
Head to Head Contrast: Spyre Therapeutics (NASDAQ:SYRE) & Aptorum Group (NASDAQ:APM) - Defense World
Charles Schwab Investment Management Inc. Has $8.84 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Bank of New York Mellon Corp Decreases Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Will Spyre Therapeutics Redefine IBD Treatment With Superior Efficacy And Convenience? - RTTNews
Spyre Therapeutics (NASDAQ:SYRE) Coverage Initiated by Analysts at Wolfe Research - Defense World
Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target -March 18, 2025 at 07:17 am EDT - Marketscreener.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Arizona State Retirement System - Defense World
Victory Capital Management Inc. Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Spyre Therapeutics Inc (SYRE) Announces Stock Option Grants to Non-Executive Employees - GuruFocus.com
132,200 New Stock Options: Inside Spyre Therapeutics' Latest Employee Compensation Package - StockTitan
Rhumbline Advisers Boosts Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status - MSN
Spyre Therapeutics Inc (SYRE) deserves closer scrutiny - US Post News
Spyre Therapeutics: Targeting The Future Of IBD Treatment - Seeking Alpha
Spyre Therapeutics (NASDAQ:SYRE) Trading 6.6% Higher After Strong Earnings - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Posts Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Buy Rating for Spyre Therapeutics Driven by Promising Drug Development and Strong Financial Position - TipRanks
Spyre Therapeutics: Q4 Earnings Snapshot - The Pioneer
Decoding Spyre Therapeutics Inc (SYRE): A Strategic SWOT Insight - GuruFocus.com
Spyre Therapeutics Reports Strong Progress and Financial Stability - TipRanks
Spyre Therapeutics reports Q4 EPS (81c), consensus (94c) - TipRanks
Spyre Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - PR Newswire
Spyre Therapeutics (SYRE) Projected to Post Earnings on Thursday - Defense World
Recent Insider Activity Could Benefit Spyre Therapeutics Inc (SYRE) - Knox Daily
SYRE Stock Touches 52-Week Low at $20.24 Amid Market Challenges - Investing.com Australia
Spyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year LowTime to Sell? - MarketBeat
Spyre Therapeutics Inc (SYRE) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):